Case 2

49F

Screening

Images

- 2018-11-21 Mammography
- 2018-12-29 Chest CT
- 2018-11-29 Breast sonography



2018-11-21 Mammography
Coarse heterogeneous microcalcification in UIQ portion of the left breast


E181
Exam: Nov 21 2018
1
1




DR DU 01
L12-5
30Hz
RS
2D
43%
Dyn R 61
P Low
Res
TAC1
TIS0.0 MI 0.7
M2
X3
11 / 2
Dist 3.37 cm
Dist 1.59 cm
4.5cm

Pathology

- Breast, 12/2 cm, left, core needle biopsy, invasive ductal carcinoma

ORIGINAL ARTICLE

US FDA Breast Implant Postapproval Studies

Long-term Outcomes in 99,993 Patients

Christopher J. Coroneos, MD, MSc, Jesse C. Selber, MD, MPH, Anaeze C. Offodile II, MD, MPH, Charles E. Butler, MD, and Mark W. Clemens, MD

Annals of Surgery Volume 269, Number 1, January 2019

TABLE 3. Rare Systemic Harms Compared With the General Population

	Manufacturer*,†	Study Events	Study Event Rate (Per 10,000 Person Yr)	General Population Event Rate (Per 10,000 Person Yr)	SIR	SIR 95% CI	*P* Value
Fibromyalgia	Allergan	9	1.8	112.8	0.02	0.01–0.03	<0.001
	Mentor	307	28.4	112.8	0.25	0.22–0.28	<0.001
Rheumatoid arthritis	Allergan	4	0.8	5.4	0.15	0.04–0.38	<0.001
	Mentor	349	32.2	5.4	5.96	5.35–6.62	<0.001
Scleroderma	Mentor	46	4.2	0.6	7.00	5.12–9.34	<0.001
Sjogren syndrome	Mentor	62	5.7	0.7	8.14	6.24–10.44	<0.001
Systemic lupus erythematosus	Allergan	3	0.6	5.4	0.11	0.02–0.32	<0.001
	Mentor	66	6.0	5.4	1.11	0.86–1.41	0.398
Cancer	Allergan	80	16.0	41.3	0.39	0.31–0.48	<0.001
	Mentor	532	63.8	41.3	1.54	1.42–1.68	<0.001
Breast cancer	Mentor	116	13.9	12.5	1.11	0.92–1.33	0.26
Lung cancer	Mentor	5	0.6	5.2	0.12	0.04–0.27	<0.001
Brain cancer	Mentor	3	0.4	0.6	0.67	0.14–1.95	0.639
Melanoma	Mentor	65	7.8	2.1	3.71	2.87–4.73	<0.001
Neurological disorder	Allergan	18	3.6	22.5	0.16	0.09–0.25	<0.001
	Mentor	394	35.8	22.5	1.59	1.44–1.76	<0.001
Multiple sclerosis	Mentor	47	4.3	2.5	1.72	1.26–2.29	0.001
Myositis	Mentor	17	1.5	0.8	1.88	1.09–3.00	0.018

*Allergan follow-up 2 years.
†Mentor follow-up 7 years.

ORIGINAL ARTICLE

Complications from injectable materials used for breast augmentation

Walter Peters PhD MD FRCSC[1], Victor Fornasier MD FRCPC[2]

W Peters, V Fornasier. Complications from injectable materials used for breast augmentation. Can J Plast Surg 2009;17(3):89-96.

Complications associées aux substances injectées pour l'augmentation mammaire

Can J Plast Surg Vol 17 No 3 Autumn 2009



Figure 3) *Mammography following silicone injections demonstrates two possible patterns: multiple cystic masses ranging from 0.2 cm to 2.0 cm in diameter, often with calcification* (**A**)*; or large areas of opacity if large volumes have been injected* (**B**)

Figure 4) *Silicone granulomas resected from breast tissue previously injected with liquid silicone*

Silicone injection and breast cancer: A systematic review of the literature

Sanjay Warrier[1,2,3,4], Cheuk Hang Cheung[1,2,3,4], Julia Rothmeier[1,2,3,4], Cindy Mak[1], Richard West[1,2], Hugh Carmalt[1,2]

The Breast 23 (2014) S1eS6

31 cases

Lymph nodal involvement: 58%
Isolated breast disease: 32%
Distant metastasis (liver, lung, bone): 10%

Ductal carcinoma: 71%
Squamous cell carcinoma: 10%
Others (mucinous, micropapillary, atypical medullary, angiosarcoma): 19%

Cases of silicone injection related breast cancer often present late with a higher incidence of nodal involvement than non silicone injection related breast cancer